MDalert.com is designed to help physicians in all specialties succeed in this new world of performance-driven healthcare.
September 21, 2021

Combined Durvalumab Consolidation Therapy Improves Outcomes in Patients With Unresectable Locally Advanced NSCLC

By Cameron Kelsall, MD /alert Contributor

The addition of oleclumab or monalizumab to durvalumab consolidation therapy improved outcomes in comparison to durvalumab monotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC)...
Combined Durvalumab Consolidation Therapy Improves Outcomes in Patients With Unresectable Locally Advanced NSCLC
September 20, 2021

Osimertinib, Bevacizumab Combination Does Not Improve PFS in Patients With EGFR-Mutated NSCLC

By Cameron Kelsall, MD /alert Contributor
Combination therapy with osimertinib and bevacizumab did not significantly improve progression-free survival (PFS) in treatment-naive patients with EGFR-mutated non–small cell lung cancer (NSCLC) when compared with osimertinib monotherapy...
Osimertinib, Bevacizumab Combination Does Not Improve PFS in Patients With EGFR-Mutated NSCLC
September 17, 2021

FDA Grants Zanubrutinib Accelerated Approval for Relapsed/Refractory Marginal Zone Lymphoma

By Adam Hochron, Staff Writer
The FDA has granted accelerated approval to zanubrutinib, a small molecule BTK inhibitor, for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen...
FDA Grants Zanubrutinib Accelerated Approval for Relapsed/Refractory Marginal Zone Lymphoma
September 16, 2021

Oral TKI Doublet a Promising Option for Patients With NSCLC, EGFR Mutations

By Cameron Kelsall, MD /alert Contributor
An all-oral doublet composed of anlotinib and gefitinib exhibited efficacy in patients with treatment-naive, EGFR–mutated advanced non–small cell lung cancer (NSCLC)...
Oral TKI Doublet a Promising Option for Patients With NSCLC, EGFR Mutations
September 15, 2021

Manufacturer Withdraws Atezolizumab from FDA Accelerated Approval for Triple-negative Breast Cancer

By Andrew John, MD /alert Contributor
Genentech has voluntarily withdrawn the accelerated approval of atezolizumab (Tecentriq) combined with albumin-bound paclitaxel as a first-line treatment for patients with locally advanced or metastatic PD-L1-positive, triple-negative breast cancer...
Manufacturer Withdraws Atezolizumab from FDA Accelerated Approval for Triple-negative Breast Cancer
View More
Loading...

Trending News

In cooperation with Reuters News and Reuters Health, we are proud to provide you with our continuously updated news feed. We select news that applies to physicians in all the major clinical specialties, as well as on finance, science, technology, and other areas.

Reuters Health Medical News

UPDATE 1-Abortion providers ask U.S. Supreme Court to intervene in challenge to Texas law

(Adds background and details on Texas law and previous Supreme Court action) By Andrew Chung (Reuters) - Abortion providers in Texas on Thursday asked the U.S. Supreme Court to intervene on an urgent Read More »

U.S. CDC advisers recommend COVID-19 vaccine boosters for ages 65 and older, those at high risk

By Michael Erman and Manojna Maddipatla (Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 Read More »

Online behavioral therapy effective for children with tics

By Lisa Rapaport (Reuters Health) - Children with Tourette syndrome or chronic tic disorder may experience more symptom improvement with remotely-delivered exposure and response prevention (ERP) Read More »

Abortion providers ask U.S. Supreme Court to intervene in challenge to Texas law

By Andrew Chung (Reuters) - Abortion providers in Texas on Thursday asked the U.S. Supreme Court to intervene on an urgent basis in their challenge to a state law imposing a near-total ban on abortion Read More »

Early exposure to World Trade Center disaster tied to higher risk for some cancers

By Marilynn Larkin NEW YORK (Reuters Health) - World Trade Center (WTC) rescue and recovery workers who arrived on the day of the disaster were at greater risk for prostate and thyroid cancers than Read More »

Residual breast cancer burden after neoadjuvant chemo predicts survival

By Marilynn Larkin NEW YORK (Reuters Health) - The residual cancer burden (RCB) after neoadjuvant chemotherapy predicted survival across all breast cancer subtypes and treatments in an analysis of the Read More »

Gender disparity in diagnosis of papillary thyroid cancer

By Lisa Rapaport (Reuters Health) - Papillary thyroid cancers are diagnosed more often in women even though incidence rates for these malignancies are similar for both sexes, a U.S. study suggests. Read More »

U.N. looks for recipe to tackle global food dysfunction

By Michelle Nichols UNITED NATIONS (Reuters) - Billions of people are overweight, millions are hungry, one third of food is wasted and the way the world produces, processes and consumes food generates Read More »

See all news »

Clinical Trials

Use our ClinicalTrials.gov feed to find trials in which your patients could enroll. In some cases, experimental drugs are a patient’s only hope. This section will regularly report on trials in the most common disease states, as they are getting underway.


© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information